Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.

UNLABELLED: Our objective was to evaluate the pharmacokinetics, normal tissue distribution, radiation dosimetry, and toxicology of human epidermal growth factor (hEGF) labeled with (111)In ((111)In-diethylenetriaminepentaacetic acid [DTPA]-hEGF) in mice and rabbits. METHODS: (111)In-DTPA-hEGF (3.6...

Descrición completa

Detalles Bibliográficos
Main Authors:	Reilly, R, Chen, P, Wang, J, Scollard, D, Cameron, R, Vallis, K
Formato:	Journal article
Idioma:	English
Publicado:	2006

Títulos similares

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
por: Bailey, K, et al.
Publicado: (2007)

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
por: Cornelissen, B, et al.
Publicado: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
por: Cornelissen, B, et al.
Publicado: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
por: Cornelissen, B, et al.
Publicado: (2012)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
por: Reilly, R, et al.
Publicado: (2004)

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
por: Cornelissen, B, et al.
Publicado: (2011)

Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
por: Vallis, K, et al.
Publicado: (2014)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
por: Costantini, D, et al.
Publicado: (2008)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
por: Costantini, D, et al.
Publicado: (2010)

A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
por: Vallis, K, et al.
Publicado: (2005)

A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer
por: Vallis, K, et al.
Publicado: (2008)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
por: Costantini, D, et al.
Publicado: (2007)

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
por: Chen, P, et al.
Publicado: (2003)

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
por: Cai, Z, et al.
Publicado: (2008)

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
por: Hu, M, et al.
Publicado: (2007)

Synergistic Effect of Keratinocyte Transplantation and Epidermal Growth Factor Delivery on Epidermal Regeneration
por: So-Jung Gwak, et al.
Publicado: (2005-11-01)

Internalization, Intracellular Trafficking, Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody
por: Rushika M. Perera, et al.
Publicado: (2007-12-01)

Association study between epidermal growth factor receptor and epidermal growth factor polymorphisms and endometriosis in a Japanese population.
por: Inagaki, M, et al.
Publicado: (2007)

Development of an epidermal growth factor derivative with EGFR blocking activity.
por: Clara Panosa, et al.
Publicado: (2013-01-01)

Epidermal Growth Factor and Intestinal Barrier Function
por: Xiaopeng Tang, et al.
Publicado: (2016-01-01)

Epidermal growth factor in the treatment of radiogenic proctitis
por: Nery González, et al.

Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.
por: Cornelissen, B, et al.
Publicado: (2005)

Epidermal Growth Factor Modulates Fetal Thymocyte Growth and Differentiation
por: Claudia S. Freitas, et al.
Publicado: (1998-01-01)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
por: Cornelissen, B, et al.
Publicado: (2009)

Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population.
por: Kitao, K, et al.
Publicado: (2007)

Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations
por: Nikolova Dafina, et al.
Publicado: (2022-09-01)

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
por: Huang-Chih Chang, et al.
Publicado: (2017-03-01)

Early signaling dynamics of the epidermal growth factor receptor
por: Reddy, Raven J., et al.
Publicado: (2017)

The effect of epidermal growth factor on serum zinc levels
por: S Demirsoy, et al.
Publicado: (1991-07-01)

Folliculitis Decalvans Due to Epidermal Growth Factor Inhibitor
por: Aurora Maria Alessandrini, et al.
Publicado: (2024-07-01)

Esophageal Cancer and the Importance of Epidermal Growth Factor (EGFR)
por: Kazem Anvari, et al.
Publicado: (2014-04-01)

Epidermal Growth Factor Expression in Middle Ear Cholesteatoma
por: Hung-Pin Chi, et al.
Publicado: (2004-01-01)

Assessment of epidermal growth factor receptor status in glioblastomas
por: Hui-Jun Zhu, et al.
Publicado: (2013-10-01)

Epidermal Growth Factor Receptor Expression in the Corneal Epithelium
por: Joanne L. Peterson, et al.
Publicado: (2021-09-01)

Modulation of Pathological Pain by Epidermal Growth Factor Receptor
por: Jazlyn P. Borges, et al.
Publicado: (2021-05-01)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors∗
por: Dipesh Uprety, MBBS, et al.
Publicado: (2020-03-01)

Epidermal growth factor receptor: Role in human cancer
por: Prashanth Rajaram, et al.
Publicado: (2017-01-01)

In ovo feeding of epidermal growth factor: embryonic expression of intestinal epidermal growth factor receptor and posthatch growth performance and intestinal development in broiler chickens1
por: Emily Kim, et al.
Publicado: (2020-11-01)

Epidermal growth factor/epidermal growth factor receptor signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells
Publicado: (2014-09-01)

A Comparison of Immunohistochemical Expression of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 in Dental Follicles with Different Radiographic Sizes
por: Shirin Saravani, et al.
Publicado: (2024-08-01)